Comparing Palatin Technologies (PINK:PTNT) & Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Palatin Technologies (PINK:PTNT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Acerus Pharmaceuticals has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are held by institutional investors. 7.1% of Palatin Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Acerus Pharmaceuticals and Palatin Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acerus Pharmaceuticals	-254.66%	-346.72%	-94.54%
Palatin Technologies	N/A	N/A	-365.57%

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Palatin Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acerus Pharmaceuticals	$7.38 million	7.71	-$18.79 million	($0.08)	-2.75
Palatin Technologies	$4.49 million	32.44	-$29.74 million	($1.55)	-3.61

Acerus Pharmaceuticals has higher revenue and earnings than Palatin Technologies. Palatin Technologies is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Acerus Pharmaceuticals and Palatin Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acerus Pharmaceuticals	0	0	0	0	0.00
Palatin Technologies	0	0	1	0	3.00

Palatin Technologies has a consensus target price of $350.00, indicating a potential upside of 6,150.00%. Given Palatin Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Palatin Technologies is more favorable than Acerus Pharmaceuticals.

Summary

Palatin Technologies beats Acerus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.